HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >

Sort by: In order: Results/Page Authors/Record:
Export metadata:
Showing results 1 to 6 of 6
TypeAuthor(s)TitleOther TitlesCitationCitation(alt)Issue Date
articleKawagishi, Naoki; Suda, Goki; Kimura, Megumi; Maehara, Osamu; Yamada, Ren; Tokuchi, Yoshimasa; Kubo, Akinori; Kitagataya, Takashi; Shigesawa, Taku; Suzuki, Kazuharu; Ohara, Masatsugu; Nakai, Masato; Sho, Takuya; Natsuizaka, Mitsuteru; Morikawa, Kenichi; Ogawa, Koji; Kudo, Yusuke; Nishida, Mutsumi; Sakamoto, NaoyaBaseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C-Scientific reports-28-Apr-2021
articleShigesawa, Taku; Suda, Goki; Kimura, Megumi; Maehara, Osamu; Tokuchi, Yoshimasa; Kubo, Akinori; Yamada, Ren; Furuya, Ken; Baba, Masaru; Kitagataya, Takashi; Suzuki, Kazuharu; Ohara, Masatsugu; Kawagishi, Naoki; Nakai, Masato; Sho, Takuya; Natsuizaka, Mitsuteru; Morikawa, Kenichi; Ogawa, Koji; Sakamoto, NaoyaBaseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma-PLoS ONE-1-Mar-2021
article (author version)Suda, Goki; Kudo, Mineo; Nagasaka, Atsushi; Furuya, Ken; Yamamoto, Yoshiya; Kobayashi, Tomoe; Shinada, Keisuke; Tateyama, Miki; Konno, Jun; Tsukuda, Yoko; Yamasaki, Kazushi; Kimura, Megumi; Umemura, Machiko; Izumi, Takaaki; Tsunematsu, Seiji; Sato, Fumiyuki; Terashita, Katsumi; Nakai, Masato; Horimoto, Hiromasa; Sho, Takuya; Natsuizaka, Mitsuteru; Morikawa, Kenichi; Ogawa, Koji; Sakamoto, NaoyaEfficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C-Journal of gastroenterology-Jul-2016
article (author version)Nakai, Masato; Ogawa, Koji; Takeda, Rei; Ohara, Masatsugu; Kawagishi, Naoki; Izumi, Takaaki; Umemura, Machiko; Ito, Jun; Sho, Takuya; Suda, Goki; Morikawa, Kenichi; Sakamoto, NaoyaIncreased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosisPredictive factors of tolvaptan efficacy for LCHepatology Research-Feb-2018
articleOhara, Masatsugu; Ogawa, Koji; Suda, Goki; Kimura, Megumi; Maehara, Osamu; Shimazaki, Tomoe; Suzuki, Kazuharu; Nakamura, Akihisa; Umemura, Machiko; Izumi, Takaaki; Kawagishi, Naoki; Nakai, Masato; Sho, Takuya; Natsuizaka, Mitsuteru; Morikawa, Kenichi; Ohnishi, Shunsuke; Sakamoto, NaoyaL-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis-Hepatology communications-Aug-2018
articleSho, Takuya; Nakanishi, Mitsuru; Morikawa, Kenichi; Ohara, Masatsugu; Kawagishi, Naoki; Izumi, Takaaki; Umemura, Machiko; Ito, Jun; Nakai, Masato; Suda, Goki; Ogawa, Koji; Chuma, Makoto; Meguro, Takashi; Nakamura, Michio; Nagasaka, Atsushi; Horimoto, Hiromasa; Yamamoto, Yoshiya; Sakamoto, NaoyaA Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma-Drugs in R&D-Sep-2017
Showing results 1 to 6 of 6

 

Hokkaido University